INTRODUCTION
More than 50% of cancer patients receive radiation therapy at least one time in their lives (1) . Radiation causes DNA damage, directly or indirectly, in all living cells, which can result in cell death, tissue damage or organ dysfunction/failure (2) . A poor understanding of the mechanisms of radiation injury has inhibited the development of agents that can effectively protect and/ or treat humans exposed to ionizing radiation. p53 protein, a transcription factor encoded by the TP53 gene, plays an important role in programmed cell death, i.e., apoptosis, in response to genotoxic stressors, including ionizing radiation (3) . More than half of human cancer cases involve mutations that impair p53 function; therefore, mutant p53 proteins have become targets of cancer therapy strategies (4) . In healthy animals with wild-type p53, it has also been shown that the inhibition of p53 protects mice from c radiation, suggesting the potential use of p53 inhibition in radioprotection (5) .
p53 and downstream effectors that regulate apoptosis have been studied by a number of groups. It has been demonstrated that ataxia telangiectasia mutated (ATM) protein activation (6) and phosphorylation of p53 protein are early biochemical events that occur in response to DNA double-strand breaks (DSBs) caused by acute exposure to c radiation (7) . Activation of p53 requires several modifications that include phosphorylation (8) , acetylation (9) and its translocation to the nucleus (10) . Activated p53 within the nucleus initiates transcription of the pro-apoptotic Bax gene (11) , which can be detected within several hours postirradiation. Bax protein ultimately causes caspase-3 and -7 activation and cell death at 24 h and later (3) . p53 is normally expressed at low levels in normal tissues (12) . Higher levels of p53 are induced after exposure to ionizing radiation (3) .
The stability of p53 plays a key role in its biological activity. Studies have shown that p53 is normally an unstable protein with a short half-life of approximately 16 min (13) . Its degradation is regulated by its posttranslational modifications and its ligation with ubiquitin by MDM2, a ubiquitin ligase (8, 14) . On the other hand, p53 is protected from MDM2-mediated degradation by heat-shock protein 90 (Hsp90), thereby prolonging its half-life and thus its cellular activity. Hsp90 is a ubiquitously expressed molecular chaperone that regulates, along with other chaperones, the folding, function and degradation of newly synthesized proteins through its ATPase activity (15) . It is known to be activated upon heat-shock stress. It is not known whether Hsp90 plays a role in healthy human cells to stabilize and activate p53 in response to ionizing radiation.
17-Dimethylamino-ethylamino-17-demethoxygeldanamycin (17-DMAG) is a derivative of the Hsp90 inhibitor geldanamycin (16, 17) . In vitro, geldanamycin selectively kills cancer cells by chelating Hsp90 in its so-called highaffinity conformation, which exists only in cancer cells (18) , and thereby prevents mutant proteins from entering the nucleus to trigger gene activation (19) . Because of the roles Hsp90 plays in key processes of tumor growth and development, including induction and stabilization of growth factors and other signals in transformed cells, angiogenesis and promotion of metastasis, Hsp90 has understandably become an inviting target in the search for pharmaceutical agents to kill cancer cells (see Discussion section for more detail).
Compared to geldanamycin, 17-DMAG is more water-soluble and distributes more rapidly in animal tissues, factors that have led to superior clinical applications in humans (20, 21) . 17-DMAG also has lower hepatotoxicity than geldanamycin (22) . Preclinical and phase 1 clinical trials have determined the pharmacokinetics of 17-DMAG in mice, rats (21) and humans (23, 24) . Human cancer studies employing a wide range of drug concentrations have shown the mean half-life of 17-DMAG after i.v. injection to be 22.3-24 h (23, 24). The drug is well tolerated over periods of months of use even when combined with other medical treatments such as radiation therapy (20) .
We recently reported that 17-DMAG protects human T cells from c radiation. This protective effect is a result of inhibition of the inducible nitric oxide synthase (iNOS)/caspase-3 cascade induced by radiation (25) . Although 17-DMAG has never been tested as a radioprotector in healthy human ex vivo cells or mice, the fact that both p53 and iNOS are clients of Hsp90 (19, 26) suggests it may prove useful. In this study we used 17-DMAG to investigate the roles of (1) Hsp90 in regulation of p53 and (2) cell death in response to acute exposure to ionizing radiation. We present evidence that 17-DMAG inhibits p53 accumulation and prevents apoptosis in irradiated human ex vivo cells by blocking acute p53 phosphorylation and its interaction with Hsp90.
MATERIALS AND METHODS

Cell Culture
TK6 and NH32 cells (generously provided by Dr. J. B. Mitchell), Jurkat cells (Clone E6-1, American Type Culture Collection, Manassas, VA), and fresh normal peripheral blood mononuclear cells (PBMCs, AllCells, LLC, Emeryville, CA) were grown in RPMI 1640 medium (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (Invitrogen), 2 mM L-glutamine (Invitrogen), 100 U/ml penicillin and 100 mg/ml streptomycin (Quality Biological Inc., Gaithersburg, MD) and maintained in a humidified 37uC incubator with continuous 5% CO 2 supply. TK6, NH32 and Jurkat cells were fed twice a week.
Drug Treatment
Cells were counted and then seeded on 6-well dishes that contained 2 ml of fresh growth medium per well and were treated with specified concentrations of 17-DMAG dissolved in water or with water alone for 24 h before irradiation.
Irradiation
Cells on 6-well dishes were exposed to 60 Co c radiation at a dose rate of 0.6 Gy/min for the time required to deliver the doses specified.
Clonogenic Assay
Five thousand cells were mixed with prewarmed, fresh RPMI 1640 medium that contained final concentrations of 40% fetal bovine serum, 2 mM L-glutamine and 0.1% low-melting-point agarose (Invitrogen) in a total volume of 3 ml. The mixture was then laid over 1 ml of solidified RPMI 1640 bottom medium (made with 1% low-melting-point agarose) in 6-well dishes. The number of colonies containing more than 50 cells was scored after 10 days of incubation.
Immunoprecipitation
Cells were disrupted by gentle agitation for 30 min at 4uC in lysis buffer, which contained 20 mM Hepes (pH 7.2-7.5) (Invitrogen), 150 mM NaCl (Sigma-Aldrich, St. Louis, MO), 0.5% Nonidet P40 (Roche; Indianapolis, IN), in the presence of protease inhibitors, phosphatase inhibitors and 10 mM sodium molybdate (SigmaAldrich). After removal of insoluble materials by centrifugation at 10,000g at 4uC, supernatants (total cell lysates) were precleared by the addition of 10 ml of protein G-agarose (Roche) and gentle rotation at 4uC for 1 h. Cleared lysates were collected after centrifugation at 10,000g for 10 min at 4uC and used for immunoprecipitation by incubating with 2 mg of the indicated antibodies and 30 ml of protein G-agarose overnight at 4uC with gentle rotation. Resulting precipitates were collected by centrifugation at 2,000g and then washed three times with lysis buffer.
Immunoblotting
Total cell lysates or immunoprecipitates were boiled in the presence of final concentrations of 13 LDS sample buffer (Invitrogen) and 10% b-mercaptoethanol (Invitrogen) for 5 min. Samples were briefly spun down and kept on ice until the separation by NuPAGEH 4-12% Bis-Tris gel (Invitrogen). Separated proteins in gels were transferred to 0.45-mm pore size PVDF membranes (Invitrogen) in the 13 transfer buffer (Invitrogen). Membranes were then soaked in blocking buffer, which contained 3% nonfat dry milk (Santa Cruz Biotechnology, Santa Cruz, CA) dissolved in Trisbuffered saline (50 mM Tris-HCl, pH 8.0, and 150 mM NaCl) supplemented with 0.2% TweenH 20 (TBS-T). Blocked membranes were reacted with primary and secondary antibodies against specific antigens and washed with TBS-T after each reaction. Resulting membranes were reacted with ECL reagents (Amersham, Piscataway, NJ) to identify bands using the manufacturer's protocol and exposed to Kodak BioMax Light films (Kodak, Rochester, NY).
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The protein band intensities were quantified by Molecular Imaging software (Kodak).
Detection of Caspase-3/7 Activity and Analysis by Confocal Microscopy
A Magic RedH Caspase Detection Kit (MP Biomedicals, Solon, OH) was used for the detection of caspase-3/7 activity following the manufacturer's protocol. Briefly, about 2 3 10 5 cells were stained in the presence of up to 300 ml of OPTI-MEM I medium (Invitrogen). Cells were seeded onto no. 1 borosilicate glass slides with 4-well chambers (Fisher Science Education, Hanover Park, IL). An LSM 5 PASCAL Zeiss laser scanning confocal microscope (Carl Zeiss MicroImaging, Thornwood, NY) with a 1003/1.3 NA Plan Apochromat oil objective was used to scan the signals. Each resulting image was provided with a simultaneous scan of differential interference contrast (DIC).
Flow Cytometry
About 10
5 cells were fixed in 13 fixation buffer followed by washing and antibody staining procedures using 13 permeabilization buffer following the manufacturer's protocol (Millipore, Billerica, MA). Stained cells were analyzed using an Guava EasyCyte MiNi flow cytometer and Guava software (Millipore).
RNA Extraction and Real-Time Quantitative Reverse Transcription-PCR (qRT-PCR)
Total RNA was extracted using RNeasy (Qiagen, Valencia, CA). Synthesis of cDNAs was performed using SuperScript II reverse transcriptase (Invitrogen), and the subsequent PCR reactions were performed using iQ Supermix (Bio-Rad, Hercules, CA) following the manufacturer's protocol. All measurements were performed on triplicate samples, each corrected by the amplification of internal control cDNA of 18S RNA. , and normal mouse IgG were obtained from Santa Cruz Biotechnology. c-H2AX and phospho-p53 on serine at position 15 were purchased from eBioscience (San Diego, CA). Primers and probes used in qRT-PCR analyses were described previously (27) .
Statistical Analysis
Statistical values were obtained from triplicate samples and shown as averages with standard errors. One-way ANOVA, standardizedrange test and Bonferroni inequality were used with significance levels set at 5 and 0.1%. IC 50 values were determined by GraphPad PrizmH (GraphPad Software, Inc., La Jolla, CA) using average values from representative experiments.
RESULTS
17-DMAG Inhibits p53 and Bax but not Bcl-2 in Human Jurkat Cells after c Irradiation
We used immunoblotting to test whether 17-DMAG would inhibit p53 and Bax protein levels after irradiation, since it was reported that (1) ionizing radiationinduced DNA damage activates p53 through phosphorylation of ATM and check 2 (CHK2) proteins (7) and (2) radiation upregulates transcription of the p53-dependent Bax gene (27) .
To observe both radiation dose-and time-dependent changes, we irradiated Jurkat cells in the presence or absence of 17-DMAG with 4 or 8 Gy 60 Co c radiation and harvested the cells 4 and 24 h postirradiation. We found radiation dose-dependent increases in p53 protein by 4 h postirradiation that were maintained at 24 h. 17-DMAG treatment effectively inhibited those increases (Fig. 1A, B) . It has been reported that p53 in Jurkat cells retains transactivation potential of the Bax gene (28) . In our study, we found similar, significant radiation dose-and time postirradiation-dependent increases in Bax protein, which were significantly inhibited by 17-DMAG treatment 24 h postirradiation (Fig. 1A, C) . Unlike with p53 and Bax, radiation did not increase Bcl-2, but 17-DMAG treatment led to a significant increase in this protein 24 h after irradiation (Fig. 1A,  D) . These data suggest the possibility that 17-DMAG exerts its radioprotective effect by inhibiting the activation of the p53-Bax pathway after radiation exposure while at the same time increasing the level of anti-apoptotic Bcl-2.
17-DMAG Inhibits Activation of p53 Pathway in Ex Vivo Human PBMCs after c Irradiation
Because human Jurkat cells are cancer cells, it is not clear whether their responses to radiation and 17-DMAG are the same as those of normal cells. We therefore tested human peripheral blood mononuclear cells (PBMCs) to determine whether there is a radiation-induced increase 
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Cells pretreated with various concentrations of 17-DMAG were left unirradiated or were irradiated with 8 Gy (Fig. 2) . We collected samples 1, 4 and 24 h postirradiation. p53 protein increased in irradiated samples at 1 h (Fig. 2A, top panel) , increased markedly at 4 h ( Fig. 2A, middle panel) , and increased further at 24 h (Fig. 2A, bottom panel) . 17-DMAG inhibited the increases in p53 protein in a concentration-dependent manner, as indicated in the samples taken 4 and 24 h postirradiation ( Fig. 2A, middle and bottom panels) . The inhibitory effect of 17-DMAG on radiationinduced increases in p53 protein is summarized in Fig. 2B . We determined an IC 50 of 0.93 ± 0.01 mM for 17-DMAG using samples collected 4 h after 8 Gy irradiation.
We next tested the effects of various doses of radiation on p53 protein levels and activation in PBMCs pretreated with or without 10 mM 17-DMAG. We collected samples 24 h postirradiation. Radiation dosedependent increases in p53 protein levels were observed, and the increases were significantly reduced by 17-DMAG pretreatment (Fig. 3A, B) . 17-DMAG also induced a slight increase in the nonirradiated samples, consistent with our previous report (29) ; however, this basal increase was much smaller than the increase induced by radiation. As with p53 protein, radiation increased the level of Bax protein, which was also significantly inhibited by 17-DMAG treatment (Fig. 3A,  C) . It was previously reported that the increase in Bax is not dependent on radiation dose (30). We did not observe significant differences in Bcl-2 levels between samples (data not shown). However, we observed significant increases in p21, another p53 target gene, which 17-DMAG inhibited (Fig. 3A, D) .
Because ionizing radiation may activate the p53-mediated Bax pathway earlier than 24 h, we hypothesized that 17-DMAG also inhibited p53 activation in samples collected at 1 and 4 h postirradiation. To test this, we first measured phosphorylation of both H2AX (c-H2AX) and p53 (pp53) in 1-h postirradiation samples. c-H2AX is a marker of DNA DSBs (31), and phosphorylation of serine at position 15 on pp53 is one of the key requirements for p53 activation (8) . We found that the increase in c-H2AX levels was radiation dosedependent, in agreement with previous reports (31) , and this response was observed both in the presence and absence of 17-DMAG (Fig. 3E) . In the same sets of samples, pp53 levels were significantly increased after 8 Gy and fully inhibited by 17-DMAG treatment (Fig. 3F) . The increase in pp53 was transient, returning to baseline levels 4 h postirradiation (data not shown). We performed similar experiments using human PMBCs and a radiation dose of 4 Gy and did not observe significant phosphorylation. This indicates that phosphorylation at serine 15 may not be the only determinant in p53 activation.
We next analyzed p53 and Bax mRNA in samples collected 4 h postirradiation to determine if any increases were correlated with their respective protein levels observed in 24-h samples (Fig. 3A-C) . Quantitative real-time RT-PCR (qRT-PCR) analysis demonstrated very little increase in p53 mRNA in irradiated samples (Fig. 3G ) but significant increases in Bax mRNA (Fig. 3H) . The unexpectedly small increase in p53 mRNA at 4 h suggested that it is not likely that enhanced transcription is the main cause of the increased level of p53 protein seen at 24 h (Figs. 2, 3A and B) . On the other hand, the increase in Bax mRNA at 4 h correlated well with protein accumulation at 24 h (Fig. 3A, C) . Treatment with 17-DMAG significantly inhibited induction of Bax mRNA, suggesting that the radioprotection effect of 17-DMAG is mediated by inhibiting the Bax pathway (Fig. 3H) . However, in the presence of 17-DMAG, the level of p53 mRNA after irradiation was significantly lower than that in vehicletreated cells (Fig. 3G) , leaving the possibility of p53 suppression at the transcriptional level in irradiated cells. Taken together, these observations support a potential role for Hsp90 in p53 protein accumulation and subsequent programmed cell death after irradiation in ex vivo human cells, because 17-DMAG, as an Hsp90 inhibitor, may impair radiation-induced p53-Hsp90 conjugation that prevents p53 from undergoing MDM2-regulated degradation (14) .
17-DMAG Does Not Inhibit Hsp90 Expression but Increases Hsp70 Expression
Because 17-DMAG is known to interfere with Hsp90 function (17), we determined whether the inhibitory effects of 17-DMAG on the radiation-activated p53-Bax pathway was due to changes in Hsp90 expression. Using PBMCs, we first looked at the effect of various concentrations of 17-DMAG on Hsp90 protein levels after exposure to 8 Gy. Membranes used for the analyses reported in Fig. 2 were reprobed with antibody directed against Hsp90, and protein levels were studied by immunoblotting and densitometric analyses. Neither radiation nor the various concentrations of 17-DMAG that were used significantly changed the levels of Hsp90 24 h postirradiation (Fig. 4A, B) . Similar data were observed in samples 1 and 4 h postirradiation (data not shown).
We next studied the effect of various doses of radiation on Hsp90 levels in the presence or absence of a 10 mM 17-DMAG pretreatment. Membranes used for the analyses reported in Fig. 3A -D were reprobed with antibody directed against Hsp90 to quantify protein levels. In these membranes, irradiation at either 4 or 8 Gy failed to change Hsp90 levels significantly (Fig. 4C, D) , 17 -DMAG INHIBITS p53-Hsp90 INTERACTION FIG. 3 . 17-DMAG inhibits radiation-induced increases in p53/Bax in normal human PBMCs. Freshly isolated PBMCs from healthy human subject were counted and seeded in medium containing 10 mM 17-DMAG or vehicle for 24 h. Cells were then irradiated, returned to the incubator, and harvested 1 h (for c-H2AX and pp53 measurements), 4 h (for mRNA measurements), and 24 h (for p53/Bax/p21 protein) postirradiation. Panel A: Representative immunoblots showing effect of 17-DMAG on p53, Bax and p21 protein after irradiation. Total cell lysates from samples collected at 24 h were prepared for immunoblots to test p53, Bax, p21 and actin expression. Levels were measured using optical densitometry. Panel B: Quantification of p53 levels relative to actin.
suggesting that neither radiation nor 17-DMAG significantly altered the level of Hsp90 protein.
Unlike Hsp90, 17-DMAG treatment significantly increased Hsp70 protein (Fig. 4A-C, E) . Ionizing radiation alone at either 4 or 8 Gy failed to alter the level of Hsp70 protein (Fig. 4A-C, E) .
17-DMAG Inhibits p53-Hsp90 Conjugation after c Irradiation
Hsp90 enhances the stability of p53 protein in cell lines by direct association with p53 after heat shock (32) . Since the data in Fig. 4 show that Hsp90 protein does   FIG. 4 . 17-DMAG has no effect on Hsp90 levels but induces Hsp70 in concentration-dependent manner in normal human PBMCs. Freshly isolated PBMCs from a healthy human subject were counted and seeded for 24 h in medium containing 17-DMAG or vehicle. Cells were then irradiated, returned to the incubator, and harvested 24 h postirradiation. Total cell lysates from samples were prepared for immunoblots to test Hsp90, Hsp70 and actin levels. Levels were quantified by optical densitometry. not increase after irradiation, we surmised the possibility of a radiation-induced increase in p53-Hsp90 complex formation that can be inhibited by 17-DMAG. To determine whether this is the case, we irradiated human PBMCs pretreated with or without 17-DMAG with 8 Gy. Cell lysates were prepared 4 h postirradiation and immunoprecipitated with anti-p53 antibody or control IgG. The precipitates were then immunoblotted with both anti-p53 and anti-Hsp90 antibodies. Analysis of immunoprecipitates indicated that Hsp90 protein from the irradiated sample lysates co-precipitated with p53 (Fig. 5) . This association occurred only in irradiated samples and was reduced with 17-DMAG treatment. We also observed a significant increase in the p53 band in the irradiated samples, and the band appeared at a position of higher molecular weight, suggesting a change in conformation due to phosphorylation. 17-DMAG also reduced this apparent conformational change. All protein recovery data from immunoprecipitation experiments were normalized to actin to account for possible variations in protein content in the samples (Fig. 5) .
17-DMAG Inhibits Caspase-3/7 Activation after c Irradiation
Caspase-3/7 activation is a key step in apoptosis. Based on our observation that 17-DMAG inhibited activation of the p53-Bax pathway after irradiation, we hypothesized that 17-DMAG treatment would also suppress caspase-3/7 activation. To test this possibly, we used samples of human PBMCs 24 h after irradiation and livestained them with Magic RedH to show caspase-3/7 activities. There was a basal level of caspase-3/7 activity in all nonirradiated samples (Fig. 6A, B, top panels) . Irradiation of vehicle-treated samples at 4 or 8 Gy resulted in significant increases in caspase-3/7 activity (Fig. 6A, B , left middle and bottom panels). Samples irradiated at either dose in the presence of 17-DMAG pretreatment demonstrated significantly lower activities than those irradiated alone (Fig. 6A, B , right middle and bottom panels). These results suggest that 17-DMAG inhibits radiation-induced increases in p53-Bax pathway activation and resulting caspase-3/7 activation.
p53 is Involved in Radiation-Induced Cell Death
Our data indicate that 17-DMAG inhibits p53-Hsp90 interactions, prevents excess p53 accumulation, and reduces caspase-3/7 activation in irradiated cells, but the data do not indicate whether there is any direct role for p53 in radiation-induced cell death. To help answer this question, we sought to determine whether there is any direct correlation between p53 inhibition and cell survival using in vitro models, which allow the study of both short-and long-term effects of genotoxic stress in living cells.
To address a possible correlation between p53 inhibition and long-term cell viability after irradiation, we compared survival rates between the normal TK6 cell line and its NH32 derivative, which is p53 deficient (Fig. 7A) . p53 has been shown to be strongly induced in TK6 cells after 4 Gy irradiation (33) . Identical numbers of cells were irradiated at various doses and seeded into soft agar medium, and the numbers of surviving colonies were determined 10 days postirradiation. Radiation reduced TK6 cell colony-forming ability in a dosedependent manner, indicating its sensitivity to radiation.
FIG. 5. 17-DMAG inhibits radiation-induced interaction between p53 and Hsp90 in normal human
PBMCs. Freshly isolated PBMCs from healthy human subject were counted and seeded for 24 h in medium containing 10 mM 17-DMAG or vehicle. Cells were then irradiated with 8 Gy or left unirradiated, returned to the incubator, and harvested 4 h postirradiation. Total cell lysates were prepared and immunoprecipitated with anti-p53 antibody or control mouse IgG followed by immunoblot analysis with indicated antibodies. Total cell lysates were also tested by immunoblot analysis for protein content by probing with anti-actin antibody.
In contrast, irradiated NH32 cells produced a significantly larger number of colonies at each radiation dose, indicating a greater resistance to radiation (Fig. 7B) . TK6 also displayed higher caspase-3/7 activity (Fig. 7C,   D , left panels) than NH32 cells 24 h postirradiation (Fig. 7C, D, right panels) . Taken together, these data reinforce the idea that 17-DMAG improves cell survival by inhibiting p53 stabilization and accumulation. 
DISCUSSION
The present study demonstrates that ionizing radiation increases p53 and Bax, but not Bcl-2, in a radiation dose-and time postirradiation-dependent manner. 17-DMAG treatment inhibits p53 in a drug concentrationdependent fashion and reduces Bax but increases Bcl-2. Cells demonstrate better survival when cells are low in p53 protein, such as when p53 is blocked by drug treatment or p53 gene knockout.
The radiation-induced increase in p53 is correlated with cell mortality (Fig. 7) (33) . Aberrant expression of or mutation in TP53 has also been observed in many cancer onsets and progressions (34) , metabolic disorders (35) and DNA damage responses (36) . Because cell viability can be altered by manipulation of p53 protein levels by techniques such as miRNA, p53 inhibitors or gene depletion (37) , p53 has been considered as a potentially useful target for developing therapeutic drugs.
Ionizing radiation causes DNA DSBs that lead to the phosphorylation of ATM protein, which leads to increases in c-H2AX (Fig. 3E ) and phosphorylated p53 (Fig. 3F) , observations that are in agreement with the literature. Phosphorylated p53 arrests the cell cycle for DNA repair through induction of the cyclin-dependent kinase inhibitor p21/cip1 (7) . When the level of p53 protein is beyond an as-yet undefined threshold, growth arrest occurs in mitotically active cells, including stem cells, and leads to senescence (38) , and the affected tissues or organs undergo apoptosis. As shown by our data, radiation initiates p53 phosphorylation instead of its transcription or translation (Fig. 3G) . p53 phosphorylation leads to increased p53 stability and accumulation (Figs. 1-3 ).
Hsp90 forms a complex with p53 after heat shock (32), which prevents p53 from being ubiquitinated and degraded (14) . Using immunoprecipitation and immunoblotting techniques, we found in human ex vivo samples that ionizing radiation induced formation of the p53-Hsp90 complex (Fig. 5) , an observation that is consistent with the literature.
The radiation-induced increase in Bax protein (Figs. 1  and 3 ) is a consequence of increases in p53 protein levels, because p53 is a transcriptional factor of the Bax gene (11) , and its activation leads to an increase in Bax mRNA (Fig. 3H) . The increase in p53/Bax resulted in increased mortality (Fig. 7B ) that was at least partly mediated by caspase-3/7-dependent apoptosis (Figs. 6, 7C and D).
p53 levels in unstressed cells are kept low as a result of continuous degradation (12) . The protein MDM2 (also called HDM2 in humans) binds to p53 (3), which blocks p53 activity as well as prevents its translocation to the nucleus. MDM2 also acts as ubiquitin ligase and covalently attaches ubiquitin to p53, marking it for degradation in proteasomes. It is suggested that p53 is protected from MDM2 after irradiation by (1) phosphorylation of the N-terminus of p53 and (2) Hsp90 binding to p53. 17-DMAG treatment inhibited both of these activities: treatment with 17-DMAG inhibited radiation-induced increases in phosphorylated p53 (Fig. 3F) , binding to Hsp90 (Fig. 5) , and thus total p53 protein (Figs. 1-3) . It is likely that nonphosphorylated p53 that is free of Hsp90 becomes the target for MDM2-mediated degradation. 17-DMAG is known to bind within the cleft between the globular domain and the beta-sheets of Hsp90 (17) , thereby leading to Hsp90 dysfunction and rapid degradation of the resulting unprotected p53.
There is an endogenous p53 antagonist in heart, namely carboxyl terminus of Hsp70-interacting protein [CHIP (39)]. 17-DMAG treatment alone significantly increased Hsp70 protein (Fig. 4A-C, E ), in agreement with previous reports (23, 24, 40) . The possibility that increases in Hsp70 involving the CHIP pathway or some other, as-yet unidentified p53 antagonist (41, 42) may play a role in the results we observe cannot yet be ruled out.
Our results demonstrate that radioprotection by 17-DMAG is related to the drug's ability to bind Hsp90 and thereby help reduce the half-life of p53 stimulated by radiation exposure. Other cellular processes involving Hsp90 could also be affected by 17-DMAG, though little is currently known of their possible role in the radiation response. In tumor cells, in addition to Hsp90-mediated stabilization of mutant proteins such as v-Src and p53 that appear during cell transformation (43), Hsp90 stabilizes various proteins in tumor cells in which there is an overexpression of growth factor receptors such as EGFR (44) and signal transduction proteins such as PI3K and AKT (45, 46) . Hsp90 is also required for induction of vascular endothelial growth factor (VEGF) and nitric oxide synthase (NOS) important for de novo angiogenesis (43, 47) . Hsp90 is known to promote the invasion step of metastasis in cooperation with the matrix metalloproteinase MMP2 (19, 48) . The effects of 17-DMAG on growth signals, stabilization of signal proteins, angiogenesis and metastasis after irradiation should be explored.
17-DMAG treatment is known to inhibit radiationinduced activation of the iNOS pathway (25) and hemorrhage-induced increases in TNF-a concentration, while it increases the anti-apoptotic protein Bcl-2 (40). It is not clear whether 17-DMAG affects FOXO protein and the PI3K/Akt pathway because UV irradiation inactivates FOXO, resulting in apoptosis (49) . It would be interesting to determine the effects of 17-DMAG on these pathways since they could all be playing a role in radiation-induced mortality.
Several reports demonstrate significantly increased radiation sensitivity of tumor cells in vivo in the presence of 17-DMAG (20) . A combination of drug treatment and radiation may prove to be a useful strategy in cancer 17 -DMAG INHIBITS p53-Hsp90 INTERACTION therapy; 17-DMAG could sensitize tumors while normal tissues could be protected from radiation injury or ischemia-induced infarction (39, 50). Importantly, loss of p53 does not significantly increase hypermutation after irradiation, while mutant p53 does (33) . Our study reveals cellular p53 level is clearly controlled by both radiation and 17-DMAG doses. Ongoing pharmacokinetics studies (21, 23, 24) may determine the optimal drug dose-and therefore p53 level-during radiation treatment in specific tissues. Our study supports the idea that 17-DMAG gives normal and cancer tissues different sensitivities to ionizing radiation, a property that could prove valuable in cancer radiotherapy in addition to the general field of radioprotection.
In summary, we have shown that ionizing radiation induces an increase in p53 and Bax in a radiation doseand time postirradiation-dependent manner. 17-DMAG treatment lowered the radiation-induced p53 increase in a drug concentration-dependent fashion by inhibiting radiation-induced p53 phosphorylation and p53-Hsp90 complex formation, thereby reducing levels of apoptosis. p53 knockout cells demonstrated reduced apoptosis, indicating the tight link between p53 and apoptosis. The results provide mechanistic insight to support further development of 17-DMAG as a radioprotector through modulation of p53.
